These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Structural Basis for the Regulation of PPARγ Activity by Imatinib. Jang JY; Kim HJ; Han BW Molecules; 2019 Oct; 24(19):. PubMed ID: 31581474 [TBL] [Abstract][Full Text] [Related]
23. GQ-16, a novel peroxisome proliferator-activated receptor γ (PPARγ) ligand, promotes insulin sensitization without weight gain. Amato AA; Rajagopalan S; Lin JZ; Carvalho BM; Figueira AC; Lu J; Ayers SD; Mottin M; Silveira RL; Souza PC; Mourão RH; Saad MJ; Togashi M; Simeoni LA; Abdalla DS; Skaf MS; Polikparpov I; Lima MC; Galdino SL; Brennan RG; Baxter JD; Pitta IR; Webb P; Phillips KJ; Neves FA J Biol Chem; 2012 Aug; 287(33):28169-79. PubMed ID: 22584573 [TBL] [Abstract][Full Text] [Related]
25. Structural and Dynamical Insight into PPARγ Antagonism: In Silico Study of the Ligand-Receptor Interactions of Non-Covalent Antagonists. Fratev F; Tsakovska I; Al Sharif M; Mihaylova E; Pajeva I Int J Mol Sci; 2015 Jul; 16(7):15405-24. PubMed ID: 26184155 [TBL] [Abstract][Full Text] [Related]
26. The nuclear receptor PPARγ individually responds to serotonin- and fatty acid-metabolites. Waku T; Shiraki T; Oyama T; Maebara K; Nakamori R; Morikawa K EMBO J; 2010 Oct; 29(19):3395-407. PubMed ID: 20717101 [TBL] [Abstract][Full Text] [Related]
27. LT175 is a novel PPARα/γ ligand with potent insulin-sensitizing effects and reduced adipogenic properties. Gilardi F; Giudici M; Mitro N; Maschi O; Guerrini U; Rando G; Maggi A; Cermenati G; Laghezza A; Loiodice F; Pochetti G; Lavecchia A; Caruso D; De Fabiani E; Bamberg K; Crestani M J Biol Chem; 2014 Mar; 289(10):6908-6920. PubMed ID: 24451380 [TBL] [Abstract][Full Text] [Related]
28. Structural basis for the inhibitory effects of a novel reversible covalent ligand on PPARγ phosphorylation. Jang JY; Kim H; Kim HJ; Suh SW; Park SB; Han BW Sci Rep; 2019 Aug; 9(1):11168. PubMed ID: 31371757 [TBL] [Abstract][Full Text] [Related]
32. Structural Basis for the Enhanced Anti-Diabetic Efficacy of Lobeglitazone on PPARγ. Jang JY; Bae H; Lee YJ; Choi YI; Kim HJ; Park SB; Suh SW; Kim SW; Han BW Sci Rep; 2018 Jan; 8(1):31. PubMed ID: 29311579 [TBL] [Abstract][Full Text] [Related]
36. PPARγ non-covalent antagonists exhibit mutable binding modes with a similar free energy of binding: a case study. Fratev F J Biomol Struct Dyn; 2017 Feb; 35(3):476-485. PubMed ID: 26872742 [TBL] [Abstract][Full Text] [Related]
37. Conformational analysis of g protein-coupled receptor signaling by hydrogen/deuterium exchange mass spectrometry. Li S; Lee SY; Chung KY Methods Enzymol; 2015; 557():261-78. PubMed ID: 25950969 [TBL] [Abstract][Full Text] [Related]
38. Cooperative cobinding of synthetic and natural ligands to the nuclear receptor PPARγ. Shang J; Brust R; Mosure SA; Bass J; Munoz-Tello P; Lin H; Hughes TS; Tang M; Ge Q; Kamenekca TM; Kojetin DJ Elife; 2018 Dec; 7():. PubMed ID: 30575522 [TBL] [Abstract][Full Text] [Related]
39. L-764406 is a partial agonist of human peroxisome proliferator-activated receptor gamma. The role of Cys313 in ligand binding. Elbrecht A; Chen Y; Adams A; Berger J; Griffin P; Klatt T; Zhang B; Menke J; Zhou G; Smith RG; Moller DE J Biol Chem; 1999 Mar; 274(12):7913-22. PubMed ID: 10075686 [TBL] [Abstract][Full Text] [Related]
40. Medium chain fatty acids are selective peroxisome proliferator activated receptor (PPAR) γ activators and pan-PPAR partial agonists. Liberato MV; Nascimento AS; Ayers SD; Lin JZ; Cvoro A; Silveira RL; Martínez L; Souza PC; Saidemberg D; Deng T; Amato AA; Togashi M; Hsueh WA; Phillips K; Palma MS; Neves FA; Skaf MS; Webb P; Polikarpov I PLoS One; 2012; 7(5):e36297. PubMed ID: 22649490 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]